Lopinavir and Ritonavir
Lopinavir and Ritonavir is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Lopinavir and Ritonavir; Generic name: LOPINAVIR AND RITONAVIR; Drug class: Cytochrome P450 3A Inhibitor [EPC].
| Brand name | Lopinavir and Ritonavir |
|---|---|
| Generic name | LOPINAVIR AND RITONAVIR |
| Drug class | Cytochrome P450 3A Inhibitor [EPC] |
| Manufacturer | Macleods Pharmaceuticals Limited |
| Used for | 1 INDICATIONS AND USAGE Lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV1 infection in adults and pediatric patients 14 days and older. Limitations of Use: Genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see Microbiology ( 12.4 )]. Lopinavir and ritonavir is an HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (14 days and older). ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Tablets: May be taken with or without food, swallowed whole and not chewed, broken, or crushed. ( 2.1 ) Adults ( 2.3 ): Total recommended daily dosage is 800/200 mg given once or twice daily. Lopinavir and ritonavir can be given as once daily or twice daily regimen. See Full Prescribing Information for details. Lopinavir and ritonavir once daily dosing regimen is not recommended in: Adult patients with three or more of the following lopinavir resistance-associated sub |
| Active ingredient(s) | LOPINAVIR |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=115178c8-5ee2-4d96-820e-ea8264c1ac10 |